[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607452":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":20,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":20,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin Treatment Arm","EXPERIMENTAL","Dosage: Start at 500 mg twice daily, titrate to 2000 mg\u002Fday (e.g., 500 mg three times daily or 1000 mg twice daily), based on tolerance.",[13],"Drug: Metformin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Metformin","Start at 500 mg twice daily, titrate to 2000 mg\u002Fday for 6 months",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hui Wei, MD","CONTACT","13132507161","weihui@ihcams.ac.cn",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":37,"coordinates":38},"Point",[39,40],117.17667,39.14222,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":45,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100607452","metformin-inhibits-dnmt3a-clonal-hematopoiesis-in-acute-leukemia-100607452",false,"NCT07188740","Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia: A Single-Arm Clinical Study","Inclusion Criteria:\n\n* Patients diagnosed with acute leukemia based on bone marrow morphology, immunology, and genetics, per WHO 2022 or ICC criteria.\n* Patients in complete remission follow-up phase with DNMT3A R882 mutation clonal hematopoiesis, VAF ≥5%.\n* Age ≥14 years, any gender\n* Laboratory requirements (within 7 days before treatment):\n\n  * Total bilirubin ≤1.5 × upper limit of normal (ULN) for age.\n  * AST and ALT ≤2.5 × ULN for age.\n  * Serum creatinine \\\u003C2 × ULN for age.\n  * Cardiac enzymes \\\u003C2 × ULN for age.\n  * Ejection fraction within normal range by echocardiogram (ECHO).\n* Signed informed consent: By patient (≥18 years) or legal guardian\u002Frelative (\\\u003C18 years or if beneficial for condition).\n\nExclusion Criteria:\n\n* Patients with diabetes receiving other medications\n* Known allergy to metformin\n* Deemed unsuitable by investigator","ALL","14 Years",{"count":56,"type":57},32,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under follow-up. Patients with DNMT3A R882 mutation (VAF ≥5%) will receive oral metformin for 6 months, with dosage gradually increased to 2000 mg\u002Fday. The primary endpoint is the proportion of patients with effective decline in DNMT3A R882 mutation VAF at 6 months. Secondary endpoints include VAF decline at 3 months, relapse-free survival (RFS) at 6 and 12 months, overall survival (OS), cumulative incidence of relapse (CIR), cumulative remission-phase mortality, and adverse event rates. Planned enrollment: 32 participants.",[63],"DNMT3A Gene Mutation",[65,66,17,67],"CHIP","acute leukemia","DNMT3A","2026-08-05",{"date":70,"type":71},"2026-08-10","ACTUAL",{"date":73,"type":57},"2026-08-30",{"date":75,"type":57},"2029-08-30",{"name":5,"class":6},1]